Interview with Dr. Hector Carvallo: Pioneer in Ivermectin, Iota Carrageenan, Bromhexine and COVID-19

By Dr. Hector Carvallo and Whiteboard Doctor
Global Research, August 30, 2021
Whiteboard Doctor 6 November 2020
Theme:

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at @crg_globalresearch.

***

This is a DO NOT MISS video!

We are extremely excited to debut this video for you all.

We interviewed pioneer and ground-breaking researcher Dr. Hector Carvallo. He is the investigator and author of the IDEA Trial and IVERCAR Trial, two ground-breaking studies on Ivermectin for the prevention and treatment of COVID-19. He has done substantial work on Ivermectin, Iota Carrageenan, Bromhexine, and more for both prophylaxis and treatment of COVID-19!

He was one of the first researchers to do significant work on treating and preventing COVID-19 with Ivermectin. He not only will help us in understanding the science and evidence behind these therapies, but will also give us a glimpse into the challenges they have faced in getting this cheap, broadly available therapeutic approved on a larger scale!

Do not miss this tremendously interesting discussion!

  • IDEA Trial – Ivermectin, Dexamethasone, Enoxaparin, Aspirin for COVID-19
  • IVERCAR Trial – Ivermectin and Iota Carrageenan Prophylaxis for COVID-19

The list of questions Dr. Carvallo will be answering/discussing:

  • Tell us a little bit about yourself.
  • What first peaked your interest in Ivermectin as a possible therapeutic for COVID-19?
  • Did you meet resistance when you first started using Ivermectin to treat COVID-19?
  • What has been your clinical experience using Ivermectin for COVID-19? What types of things have you observed that may not be easy to grasp by reading your research?
  • What do you think is preventing Ivermectin from becoming more heavily considered by the world as a therapeutic for COVID-19?
  • After the ICON Trial was published in Chest, more physicians seem to be publicly supporting the use of Ivermectin for COVID-19. What do you think it will take for the larger medical industry to start to pay attention to this potential therapeutic?
  • What do you want our viewers to know about COVID-19, your research, or your ground-breaking work on Ivermectin?
  • What is Iota Carrageenan and how did you first get interested in this compound?
  • What has been your clinical experience using this medication for COVID-19?
  • There seems to be mixed literature on whether Bromhexine is efficacious. What are your thoughts on it’s efficacy?
  • Do you think that we will find a single agent to treat COVID-19, or do you believe it will be a combination of different medications? What might that combination look like?
  • What are you looking at right now? Any interesting or impressive data that has yet to be published that you would like to share with our viewers?
  • Any other things you would like to discuss with our viewers?

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is a screenshot from the video

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]